Logo image
694: Is lowering the diagnostic threshold for gestational diabetes (GDM) cost-effective? Implications from the hyperglycemia and adverse pregnancy outcomes (HAPO) trial
Abstract   Open access   Peer reviewed

694: Is lowering the diagnostic threshold for gestational diabetes (GDM) cost-effective? Implications from the hyperglycemia and adverse pregnancy outcomes (HAPO) trial

Sarah Lee, Christian Pettker, Edmund Funai, Errol Norwitz and Stephen Thung
American journal of obstetrics and gynecology, Vol.199(6 Suppl A), pp.S199-S199
12/03/2008
DOI: 10.1016/j.ajog.2008.09.725
url
https://doi.org/10.1016/j.ajog.2008.09.725View
Published (Version of record) Open Access

Abstract

Objective The HAPO TRIAL demonstrates a progressive increase in maternal and neonatal adverse outcomes at maternal glucose levels below those diagnostic for GDM. We sought to determine if there is a cost-effective 2-hour glucose tolerance test (GTT) cut-off below the threshold currently used by the World Health Organization (140mg/dL). Study Design We created a decision model comparing the direct societal costs and outcomes of mother and offspring with respect to different 2-hour GTT diagnostic thresholds. Potential cut-offs examined from the HAPO TRIAL included: category 3 (109 mg/dL), category 4 (126 mg/dL), and the current standard category 5 (140 mg/dL). Important factors in the model included: increasing risk for preeclampsia and shoulder dystocia with increasing 2-hour GTT results and the potential prevention of these events with a diagnosis and treatment of GDM as previously demonstrated (ACHOIS TRIAL). We computed the incidence of adverse outcomes such as permanent brachial plexus injury (BPI) and maternal death due to preeclampsia. Additionally, the costs of diabetes care, long-term health care for injured offspring, and preeclampsia management were factored into the model. The main outcome measure was marginal cost per QALY gained (ICER) for mother and offspring. An ICER of <$50,000 per QALY gained was considered cost-effective. Univariate sensitivity analysis was conducted to examine the robustness of the findings. Results When compared to a 140mg/dL threshold, a 126mg/dL threshold had an ICER of $76,000 per QALY gained. Furthermore our model predicts that a 126mg/dL threshold will prevent 5 additional maternal deaths and 140 cases of permanent BPI for every 10,000,000 women screened. The model was sensitive to changes in multiple parameters (ICER <$50,000); especially those concerning the prevalence, cost of management, and magnitude of prevention of preeclampsia in this cohort. Conclusion Our model predicts that lowering the 2hr GTT cut-off below 140mg/dL (WHO) does not appear cost-effective.

Details

Metrics

1 Record Views
Logo image